DIAGNOS Announces the Creation of Indian Subsidiary and the Opening of an Office in India

DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in
healthcare technical services including, screening, software and algorithm
development, data analysis, and image processing, announces today the Creation
of Indian Subsidiary and the Opening of an Office in Mumbai, India, to support
and coordinate deployment and usage of CARA in India.


To execute on the LOI signed with a major global pharmaceutical company in
India, announced on September 4th 2013, Diagnos has created a local subsidiary:
DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED. The subsidiary is incorporated in
Mumbai, Maharashtra, India, under the Indian Companies Act, as a private limited
company approved by ANURADHA BHASKAR ATHAVALE, Deputy Registrar of Companies.


The official Indian address as per record deposited and available in the Indian
Registrar of Companies office is:




DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED                                  
Platinum Techno Park 17 & 18, Level 13,                                     
Sector 30 Vashi, Navi Mumbai, 400705, Maharashtra, INDIA                    



"The Mumbai office will serve as a coordination centre for Mumbai, and New Delhi
mobile screening units (comprising our CARA platform, screening van, licensed
optometric screener, and driver), which will initially cover territories with
500km radius around the respective cities, and traveling to cities, towns, and
villages in the designated coverage areas to conduct mobile screening camps in
association with participating primary and tertiary healthcare institutions. Our
India office will also serve as a coordination point for activities in the
broader region, which will comprise India and the Middle East." Said Peter
Nowacki, Diagnos' Vice-President - Healthcare.


About CARA 

CARA is a tele-ophthalmology platform that integrates with ophthalmic imaging
equipment (hardware and software) and processes at the point of care (POC) and
comprises: image upload, image enhancement automated pre-screening, grading by a
specialist, and referral to a specialist. CARA's image enhancement algorithms
make standard retinal images sharper, clearer, and easier to read. CARA is
accessible securely over the internet, and is compatible with all recognized
image formats and brands of fundus cameras, and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients, in real-time and
has been approved by regulatory authorities including Health Canada, US Food and
Drug Administration, and the European Union.


About DIAGNOS 

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a
mission to commercialize technologies combining contextual imaging and
traditional data mining thereby improving decision making processes. DIAGNOS
offers products, services, and solutions to clients in a variety of fields
including healthcare and natural resources.


Neither the TSX Venture Exchange nor its Regulation Service Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


For further information on DIAGNOS, please visit our website at www.diagnos.com
or the SEDAR website at www.sedar.com.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Andre Larente, President
DIAGNOS inc.
1-877-678-8882 or (450) 678-8882, ext.: 224


Louis Morin
Bid Capital Markets
514-845-1101

Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024